Back to Search
Start Over
Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months.
- Source :
-
Pediatric blood & cancer [Pediatr Blood Cancer] 2021 May; Vol. 68 (5), pp. e28977. Date of Electronic Publication: 2021 Feb 25. - Publication Year :
- 2021
-
Abstract
- Inhibition of platelet activation may reduce vaso-occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months). All patients had measurable ticagrelor plasma concentrations. Ticagrelor and active metabolite (AR-C124910XX) exposure were comparable across all groups (<6 months, ≥6 to <12 months and ≥12 to <24 months). Ticagrelor was well tolerated. Palatability was generally acceptable. These data will be used to enable dose selection for further investigations of ticagrelor efficacy and safety in children with SCD.<br /> (© 2021 Wiley Periodicals LLC.)
Details
- Language :
- English
- ISSN :
- 1545-5017
- Volume :
- 68
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Pediatric blood & cancer
- Publication Type :
- Academic Journal
- Accession number :
- 33629819
- Full Text :
- https://doi.org/10.1002/pbc.28977